The pharmacologic activity of tapentadol is due to both muopioid receptor (MOR) agonism and norepinephrine reuptake inhibition. In models of acute pain, 2 tapentadol was only 2 to 3 times less potent than morphine, despite a 50-fold lower affinity for the MOR than morphine in vitro. The combination of low MOR affinity with only a modest decrease in analgesic potency suggests that the norepinephrine reuptake inhibitory effect of tapentadol is a major contributor to its analgesic effects. In addition, tapentadol was associated with very weak, dose-independent emetic effects 3 and decreased effect on gastrointestinal motility when compared with oxycodone.
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Topics in Pain Management is indexed by SIIC (Sociedad Iberoamericana de Información Científica). is presented in Table 1 . Chemical structures for tapentadol and tramadol are shown in Figures 1 and 2 . A single oral dose of tapentadol is rapidly absorbed, then excreted into the urine, primarily in the form of conjugated metabolites. The dose is usually tolerated well. 4 After oral administration, 32% of the drug is absorbed and widely distributed in the body. The plasma protein binding is low and amounts to approximately 20%. The activity of tapentadol is independent of metabolic activation and resides in a single enantiomer that readily crosses the blood-brain barrier; hence, tapentadol displays a rapid onset of action after administration. The half-life is 4 hours. Peak effect is attained after 1 hour. Duration of action is 4 to 6 hours. The drug undergoes extensive first-pass hepatic metabolism (i.e., 97%).
In contrast, tramadol's mechanism of action 5 is due to two complementary mechanisms: binding of the parent and the M1 metabolite to the mu receptors and weak inhibition of reuptake of norepinephrine and serotonin. The M1 metabolite (O-demethylated tramadol) is 6 times more potent in producing analgesia and 200 times more potent in binding to the mu receptor than the parent compound. The pure mu agonists have only a single mechanism of action, and their metabolites may have both analgesic and algesic properties.
Tapentadol metabolites have no analgesic activity. 6 The biotransformation of tapentadol by metabolic enzymes results in deactivation, i.e., tapentadol has no active metabolites, and the main metabolic pathway for elimination is phase II glucuronidation.
Phase I biotransformations, such as hydroxylation and Ndemethylation, play only a minor role in the metabolic fate of tapentadol. Owing to the minor involvement of phase I metabolic pathways, tapentadol has a low potential for drug-drug interactions and interindividual variability. In patients taking tapentadol, 99% of the drug is excreted renally.
Tapentadol has not been shown to inhibit or induce P450 enzymes. 7 Therefore, clinically relevant interactions mediated by the cytochrome P450 system are unlikely to occur.
There were no clinically significant findings in drug interaction studies of tapentadol with acetaminophen, acetylsalicylic acid, naproxen, and probenecid; nor were interactions seen with omeprazole and metoclopramide.
Drug Interactions
Tapentadol use is contraindicated within 14 days of using a monoamine oxidase (MAO) inhibitor. Tapentadol should be used with caution in patients using other centrally acting In contrast, tramadol is significantly affected by the concomitant use of CYP2D6 inhibitors such as fluoxetine, paroxetine, and amitriptyline and CYP3A4 inhibitors such as ketoconazole and erythromycin. Postmarketing surveillance of tramadol has shown that there is an increased risk of serotonin syndrome with the concomitant use of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or MAO inhibitors. Serotonin syndrome has also been reported to occur when tramadol and alpha-2 blockers (e.g., clonidine) are co-administered.
Serotonin Syndrome Risk
The serotonin syndrome was previously reviewed in TPM (vol. 22, no. 3, October 2006). Serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, seizures, coma); autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia); neuromuscular aberrations (e.g., hyperreflexia, incoordination); and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients with serotonin syndrome require symptomatic support in an intensive care unit. Serotonin syndrome is associated with a significant risk of mortality.
Dosing
Tapentadol may be taken orally with or without food. Therapy can be initiated with a dose of 50, 75, or 100 mg every 4 to 6 hours, depending on pain intensity. On the first day of dosing, the second dose may be administered as soon as 1 hour after the first dose, if adequate pain relief is not attained with the first dose. The dose should be adjusted to maintain adequate analgesia with acceptable tolerability. No dosage adjustment is required in patients with mild to moderate renal impairment. Use is not recommended in patients with severe renal impairment or end-stage renal disease. This is because 99% of the drug is excreted renally. 8 No dosage adjustment is needed in patients with mild hepatic impairment. Tapentadol should be used with caution in patients with moderate hepatic impairment, with the dose initiated at 50 mg and the interval between doses no less than every 8 hours, for a maximum of 3 doses in 24 hours. The interval may be adjusted to achieve maintenance of analgesia with acceptable tolerability. Tapentadol use is not recommended in patients with severe hepatic impairment. 9 In contrast, dosing for tramadol is twice daily, and oxycodone immediate release (IR) is taken every 4 to 6 hours. There are, of course, extended-duration versions of a wide range of opiates and tramadol.
There is no extended-release version of tapentadol currently on the market, although studies of an extended-duration formulation are published.
Geriatric Patients
In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses. 9 
Pediatric Patients
Safety and efficacy in pediatric patients younger than 18 years of age have not been established; therefore, use of tapentadol in this population is not recommended.
The Drug Enforcement Administration 10 has listed tapentadol in schedule II, similar to morphine and oxycodone. In contrast, tramadol is a schedule IV drug.
Pain Studies of Tapentadol

Postoperative Pain After Bunionectomy
In a study 11 comparing tapentadol with morphine and ibuprofen for relief of pain after foot surgery, tapentadol produced equally good pain relief with less nausea and dizziness. Data from a randomized, double-blind, phase III study 12 comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain led to the conclusion that multiple doses of tapentadol IR (50, 75, and 100 mg) significantly relieved acute pain with improved gastrointestinal tolerability.
These two studies are important because they are head-tohead trials with other established acceptable methods of analgesia. In addition, they demonstrate a quantifiable advantage in side effects.
Other Studies Postsurgical Dental Pain
Single oral doses of tapentadol 75 mg or higher effectively reduced moderate to severe postoperative dental pain in a dose-related fashion and were well-tolerated compared with morphine. 13 This is the FDA's standard approach to assessment of analgesic effectiveness and establishes the dosing range for moderate (visual analog score greater than 4/10) to severe pain.
Pain From Osteoarthritis of Hip or Knee
In a phase II randomized, placebo-controlled dose-ranging trial, 14 it was observed that in addition to comparable efficacy, treatment with tapentadol 200 mg resulted in fewer adverse events compared with oxycodone in relieving pain due to osteoarthritis of the knee. Here again, the advantage of decreased side effects was statistically significant.
Pain From End-Stage Joint Disease
Hartrick et al. 15 observed significant relief from pain with the 50-mg or 75-mg dose of tapentadol in patients with end-stage joint disease compared with placebo (P < 0.001). This study is very interesting due to the use of only a placebo as a comparator. It is definitive proof of analgesic efficacy.
Chronic Low Back Pain
A phase III randomized, double-blind study 16 evaluated the tolerability of tapentadol 50 and 100 mg IR and oxycodone IR for low back pain or osteoarthritis pain over an extended period (90 days). Tapentadol was associated with better gastrointestinal tolerability while providing similar analgesic potency.
It is important to note that this study provides evidence for long duration of analgesia, which is not studied by most manufacturers.
Adverse Effects
Gastrointestinal Side Effects
Evaluation of data from the same trial of tapentadol for chronic low back pain 16 also demonstrated significantly improved gastrointestinal tolerability compared with oxycodone IR for treatment of acute pain. Tapentadol was well tolerated when taken for up to 90 days.
Gastrointestinal events, including nausea (18.4% vs. 29.4%), vomiting (16.9% vs. 30.0%), and constipation (12.8% vs. 27.1%) were reported by 44.2% of patients receiving tapentadol IR and 63.5% of patients receiving oxycodone IR, respectively. 16 In contrast, tramadol and the pure opiate agonists have a statistically significantly higher rate of GI upset.
Respiratory Side Effects
Due to its MOR agonism, respiratory depression can occur as a result of tapentadol administration. Respiratory depression was found to occur more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Tapentadol should be used only under careful medical supervision at the lowest effective dose in such patients. 17 There are no significant differences in CO 2 response curves among the pure mu agonists, tramadol, and tapentadol.
Drug Overdose
Experience with tapentadol overdose is limited. Management of the patient with suspected overdose should be focused on treating symptoms of MOR agonism. Primary attention should be given to reestablishment of a patent airway and institution of controlled ventilation. Supportive measures (including O 2 and vasopressors) should be used in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. The pure opioid antagonists, such as naloxone and nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose.
Gastrointestinal decontamination with oral charcoal may be considered to eliminate any unabsorbed drug. This should be attempted only after the airway has been secured. Activated charcoal and gastric lavage is recommended only within 2 hours after intake. After the 2-hour window, gastrointestinal decontamination may be helpful only in cases of intoxication with exceptionally large quantities of the drug. 17
Contraindications
Monoamine Oxidase Inhibitors
Tapentadol is contraindicated in patients who are receiving MAO inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events and the serotonin syndrome.
Misuse and Abuse
Although concerns about abuse and addiction should not prevent proper management of pain, all patients treated with tapentadol should be assessed prior to initiation of therapy for potential for misuse and abuse of the drug. A history of drug abuse, alcoholism, or asking for the medication by name are "red flags" that should alert the practitioner to potential problems.
Tapentadol can be abused in a manner similar to other muopioid agonists, legal or illicit. It can be abused by crushing, chewing, snorting, or injection. These practices pose a significant risk to the abuser and can result in overdose and death. It is very important to note that current urine toxicology
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Respiratory depression can occur as a result of tapentadol administration.
Management of the patient with suspected overdose should be focused on treating symptoms of mu-opioid receptor agonism.
Tapentadol can be abused in a manner similar to other mu-opioid receptor agonists, legal or illicit.
screens will not detect the presence of tapentadol. In contrast, tramadol, which is metabolized to a codeine conger, will be detectable in the urine. The pure mu agonists are readily detectable with a wide range of tests.
Seizures
Tapentadol should be prescribed with care in patients with a history of a seizure disorder or any other condition (alcoholism, history of head injury, metabolic disorders) that would put the patient at risk of seizures. This is similar to tramadol, which also increases the risk of seizures in patients with a history of seizures. The pure mu agonists do not share this risk.
Withdrawal
Withdrawal symptoms 18 may occur if tapentadol is discontinued abruptly after 2 weeks of continuous use. Symptoms may include anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and, rarely, hallucinations. Withdrawal symptoms may be reduced by a slow taper of tapentadol over the course of several days. The use of clonidine and benzodiazepines-which are frequently employed to treat these withdrawal symptoms-has not yet been studied.
Pregnancy and Lactation
There are no adequate and well-controlled studies of tapentadol in pregnant women. It is considered a class C drug with regard to its use in pregnancy (i.e., it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus). Tapentadol is not recommended for use in women during and immediately prior to labor and delivery. Neonates whose mothers have been taking tapentadol should be monitored for respiratory depression. It should not be used during breastfeeding. This is similar to tramadol, which is also class C and should be avoided if the patient is breastfeeding. The pure mu agonists, in contrast, can be used during pregnancy, but again, there is a risk to neonates that they may suffer from sedation and respiratory depression if tramadol is used during labor and while breastfeeding.
The average daily cost of tapentadol is $8.16 to $19.08 based on a range of 50 to 100 mg q6hrs. The average daily cost of tramadol generic is $0.85 to $1.60 based on a range of 50 to 100 mg BID. In contrast, generic opiates with comparable analgesic strength are available for less than $2 per day.
Conclusions
Tapentadol is a new analgesic drug with a dual mode of action, and it has demonstrated efficacy in a number of acute and chronic pain models. Because it has fewer gastrointestinal side effects than other opiate drugs, it may be better tolerated in patients susceptible to nausea, vomiting, and constipation and may provide a useful second-line alternative to opiates.
Tapentadol combines moderate MOR agonist activity with norepinephrine reuptake inhibition in a single molecule. No metabolic activation of tapentadol is necessary for analgesia, and it has no active metabolites. Further randomized controlled trials are needed to establish routine postoperative use. I I 
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Ketamine continues to draw great interest as a treatment for complex regional pain syndrome type 1 (CRPS-1), also called reflex sympathetic dystrophy (RSD). However, its use is not widespread, as insurers and others say more data need to be collected on how to treat patients with this relatively inexpensive drug that is already used as an anesthetic.
In fact, researchers in Germany and Mexico have administered anesthetic doses of ketamine to CRPS patients to induce a coma state for 5 days. About half of these patients have emerged with reports of being cured, says Robert J. Schwartzman, MD, chair of the Department of Neurology at Drexel University in Philadelphia.
Schwartzman is a pioneer in CRPS/RSD research and one of the most widely published authors on this topic. Before coming to Drexel in 1995, he chaired the Department of Neurology at Thomas Jefferson University for 13 years. From 1978 to 1992, he was professor of neurology, chief of the Division of Neurology, and program director at the University of Texas Health Science Center, San Antonio. He has been recognized as a humanitarian by the RSD/CRPS patient advocacy groups and is a founding member of the Scientific Advisory Board for the Reflex Sympathetic Dystrophy Association of America. He established the first RSD clinic in the United States and has won major teaching awards from all of the universities where he has served. He has received a grant from the Tilly Family Foundation working to better understand RSD, its cause, progression, and mechanisms. He currently has several clinical trials underway working with doctors here and abroad.
Shwartzman's reach has included not only the patients he served, but also the physicians he has trained: more than 240 residents during his career. Of those, 30 have become professors of neurology and six have gone on to chair neurology departments. He has been caring for patients with this chronic pain state for more than 40 years, and he thinks that physicians have the ability, with ketamine, to cure many patients and at least alleviate some of the pain and symptoms.
Although he would like to see more study of the anesthetic dose, he thinks that data from his trials with ketamine at a subanesthetic dose in the outpatient setting are strong enough that this treatment should be offered to patients now.
This use of ketamine would be off-label and probably not covered by insurance, but there have been at least some cases in which patients have successfully asked their insurer to cover it, and the insurer did. (See article, page .)
Schwartzman was the lead author on one of two recently published studies of this use of ketamine. Results from these two randomized, placebo-controlled, double-blind clinical trials were published last fall. They show that ketamine infusion at subanesthetic levels provided sustained relief from CRPS-1. Schwartzman et al. studied outpatients. 1 The other study, by Sigtermans et al., of Leiden University Medical Center in Leiden, The Netherlands, was similar in many ways. In the Sigtermans study, however, participants were treated as inpatients. 2 These two recent studies published in Pain, the journal of the International Association for the Study of Pain, describe results in which participants received either placebo or ketamine infusions and reported long-term relief of pain. They are important additions to the body of evidence showing this treatment holds promise for patients suffering from this often-refractory condition.
In Schwartzman's latest study, 19 participants completed the study. Nine received an infusion of 0.35 mg/kg/hr, not to exceed 25 mg per hour, of ketamine in a saline solution for a total of 4 hours per day for 10 days, on an outpatient basis. The 10 subjects in the placebo group received only saline. Both groups also received clonidine and midazolam. Participants in
Conversation: Robert J. Schwartzman, MD, Pioneer in CRPS Research, on the Use of Ketamine Infusion and Prospect for Greater Access
the placebo group demonstrated no treatment effect in any parameter, but those who received ketamine had a statistically significant reduction in pain according to several parameters. 1 The authors wrote that they originally intended to include 20 participants in each arm of the study, for a total of 40. However, they stopped at the halfway point because an interim analysis revealed there was very little placebo effect in the 19 patients who had completed the study. This allowed the authors to achieve statistical significance with a lower number of participants than originally planned, they wrote.
They also found, over the 2-year duration of the study, that a higher dose of 50 mg of ketamine per hour (a total of 200 mg during the 4 hours of administration) provided much greater pain relief for a longer period, without any complications. This month, we speak with Schwartzman, who is passionate about advocating for increasing access to ketamine infusion for CRPS patients who could benefit from it. Schwartzman uses a word-cure-that physicians often avoid, especially when talking about CRPS and other refractory pain conditions. Ketamine, he says, has literally cured some patients and has enabled many others to feel much less pain.
TPM: Tell us about the infusion treatment. What do the patients do while they are being infused?
Schwartzman: They're sleeping. We have them sit in a reclining chair for the infusion. They have nurses who start their IVs. Their oxygen saturation is monitored. They receive cardiac monitoring during the procedure. Their blood pressure is monitored. They fall asleep while we give them the ketamine and the midazolam.
And then I see them when they wake up. I go over the various dosages with them. We examine them, we record it, and then they go home. They're tired afterwards, so they go home and sleep, and then they get up and they're normal the rest of the day. They come back the next day, and we infuse them again. TPM: Dr. Sigtermans said he thought the inpatient setting was better because of the potential for psychomimetic effects, and nausea and vomiting are also side effects of ketamine. Do you still think it can be done in an outpatient setting?
Schwartzman: Most clinicians should be able to manage patients' side effects through adjusting the dose and administering midazolam.
Those who raise the issue are looking at all the rodent models, and the scientists working on rodent models are always talking about these horrible side effects with no idea that clinicians-the guys that take care of patients-know how to use midazolam, and so you don't get these side effects. TPM: Does the effect of the drug last for 11 weeks for most of the patients? Schwartzman: Everybody's different, but I would say the effect was lasting between 2 and 4 months, by the time we were done with the whole study. And the effects were dramatic-these patients were functioning again. That was at the 50-mg dose.
They come back for 2 months, two to three visits, and then they go on to other business. TPM: Does the effect wear off gradually for them, or all at once? Schwartzman: Yes, gradually. They know it's coming back. They don't panic, after they see it can go away again with another course of the ketamine. When we first started, we didn't know how to do this very well. Patients would really panic when their symptoms began to return. Now, they just call me and say, "I can feel this wearing off." We try to do it with just two treatments, and if that's not enough, I can tell. When the symptoms are active, the patients are sweating. They are swollen and red and they can't move fast enough. The areas where they are hot and when they're touched, it really hurts. But I can tell how we're doing because the redness goes away right away. You can see they move their fingers faster. TPM: Right away? Schwartzman: Right away. I mean 4 hours after they're infused. They're better. They're not perfect, but they're better.
Ketamine's out of your body in 12 hours, but it resets the NMDA receptor. So it's out of your body, but it's changed the pain receptor. And this is very plastic business. You can make a new protein after you're hurt, in a matter of 12 hours. I mean, it's very quick. It's dynamic and it's fast. TPM: Hasn't ketamine also been associated with better outcomes when used as a preoperative infusion for patients with CRPS who are undergoing major surgery?
Schwartzman: We started the concept of adding ketamine during surgery so that the patient doesn't develop RSD, it prevents a recurrence or exacerbation if you already have RSD. If you use ketamine during surgery, you don't spread it and you don't make it worse. There is no literature supporting this, but it needs to be written.
It's being done now because the anesthesiologists are putting the patient to sleep anyway for the surgery, and there's no big extra cost to adding ketamine to the infusion. I would say, of the anesthesiologists treating patients in this country, maybe 15% are doing it, which isn't very much. It should be 95%. They should put me out of business. I shouldn't see anybody.
I'm serious. I want to be put out of business. I hate seeing these people suffer. It's awful. And the ones that I see are just pitiful. Schwartzman: I started working with RSD patients because a nurse's daughter twisted her ankle and got terrible RSD. The nurse just pestered me until I started working with this kid, and the next thing you know I had another kid come with this condition, and the next thing I knew, I had another. And everybody else hates these patients because they get really sick and they're demanding, and they hurt. And they don't seem to get better. Doctors hate that. So then, all of sudden, Dr. Schwartzman was the place to send your patients. TPM: And that was how long ago? Schwartzman: Forty years. And now, I have seen approximately 8000 people with this. I currently have 1500 active patients that I see with CRPS/RSD. TPM: You don't seem to be slowing down. Schwartzman: Whatever it takes, we need to get this treatment to the people who need it. It's ridiculous. We could cure them. TPM: Are you urging physicians in pain management and other advocates for pain care to ask legislators and regulators to compel coverage of ketamine for CRPS when it is indicated? Schwartzman: Yes. Some day, it will change. I've done my best, and we know how to really fix this. TPM: What role do patients play in advocating for change? Schwartzman: Patients will begin to demand what's right, too. The Internet has changed all of this for patients. They talk to each other, they have support groups, and they know what's going on 20 times more than some of the doctors do.
Look at it this way: A lot of Americans would rather die than spend any money on health care, but these patients-a lot of them are paying for the ketamine treatment on their own because insurance won't pay it, because it works. I make it as inexpensive as I can, and we treat a lot of people for free. I The Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) is advocating for more research to guide clinicians and regulators in the appropriate use of ketamine infusion to treat complex regional pain syndrome (CRPS), also known as reflex sympathetic dystrophy (RSD).
The 25-year-old support and advocacy organization has heard from members who have been treated with ketamine infusion.
"We hear that it is not a cure, [but] may help and often does," said James W. Broatch, MSW, executive director of the RSDSA. "However, individuals often need additional ketamine treatments."
For those whose physicians have recommended ketamine, the problem often is insurance coverage. But some patients have persevered in seeking coverage and have succeeded, Broatch said. "We have discovered that individuals are receiving sporadic reimbursement for the subanesthetic dose," he said.
In the RSDA's fall 2009 newsletter, the mother of an athletic teen-age boy wrote of his successful outcome after struggling for more than 2 years with CRPS. He developed the condition after falling on his tailbone on hard ground at age 13. He underwent two years of procedures, including several blocks and eventually the subanesthetic dose of ketamine infusion. The parents were able to get their local hospital review board to approve the procedure, using the guidelines of Robert Schwartzman, MD, of Drexel University in Philadelphia (See article, page 7.)
The teens's doctor managed to get the family's Blue Cross Blue Shield insurance to cover the ketamine infusions-two 5-day infusions and four booster infusions.
Although the ketamine helped and caused his pain score to drop to 2.5 on a scale of 10, the effect wore off a month after the infusions. The parents were considering traveling to Mexico to enroll their son in a trial of the anesthetic dose of ketamine, which has not been approved in the United States.
However, the patient'mother, who is a physical therapist, learned of the Reflex Neurovascular Dystrophy program run by David Sherry, MD, at Children's Hospital of Philadelphia. The boy participated in an intensive day program comprising 6 hours a day of intense physical therapy, occupational therapy, and desensitization as well as art and music therapy and psychology. little pain and normal function. Now 16, he has returned to a normal, active life of school and athletics.
Broatch said the two studies published in the fall, including Schwartzman's, will help pave the way for more insurers to cover the procedure consistently, as long as more data are developed about patient selection.
"We are very pleased that Dr. Schwartzman has published his controlled study and that may begin to increase coverage," Broatch said. "We have not issued any position paper advocating insurance reimbursement. Additional studies are needed. Dr. Schwartzman et al. need to develop inclusion criteria for who might benefit by this intervention."
Some people choose to pay the cost out of pocket-about $3000, according to Schwartzman-rather than wait for coverage.
Broatch said ketamine is one of the high-profile treatments that patients are watching.
"There is intense interest in ketamine in the CRPS community," Broatch said. "To our knowledge, there are very few physicians-we do maintain a small referral listutilizing this method. Long-distance travel-which is incredibly difficult for individuals in chronic pain-is often necessary."
Broatch does not expect skepticism among physicians, and he thinks that the sporadic coverage is the main reason more are not offering the treatment.
"I have found that the majority of pain specialists are procedure-oriented, and when insurance coverage is more readily available, they will quickly embrace interventions with ketamine," Broatch said.
One member of the board is an insurance industry executive. Broatch said he has not approached her about coverage for ketamine, specifically.
"But she has helped us to dialogue with the insurance industry regarding coverage issues, especially the poor reimbursement related to the lack of evidence for most CRPS therapies," Broatch said. "We interface with so many individuals who have not responded to current therapeutic options; yet we do advocate for and see the tremendous value of treatment at multidisciplinary care pain centers-which are too rare! "Sadly, most individuals with CRPS still receive fragmented care: [for example] they respond to a nerve block, yet are not referred for physical therapy or occupational therapy," Broatch said.
Other therapies they are watching include mirror box therapy and graded motor imagery for acute CRPS.
The organization advocates, more than anything, "staying active, learning that you must not allow CRPS to define your life," Broatch said. Sadly, most individuals with CRPS still receive fragmented care.
UCLA Pain Center Offers Ketamine Infusion
One of the physicians that Broatch refers patients to is Joshua P. Prager, MD, MS, director of the Center for the Rehabilitation Pain Syndromes (CRPS) at UCLA Medical Plaza and clinical assistant professor of anesthesiology and internal medicine at UCLA's David Geffen School of Medicine.
Prager has found patients need one to three infusions of 4 hours each, repeated after 3 to 4 months. His center has been using this infusion therapy to treat patients with CRPS for more than 4 years.
The results, he said, have been "superb in bona fide CRPS patients, [but] not as good in other neuropathic pain syndromes." Any side effects, including nausea and psychomimetic effects, he said, have been very manageable, but patients should be appropriately selected. "We avoid patients with respiratory or cardiac problems," Prager said. "We have treated patients with bipolar disease. When peripheral intravenous access is a problem, we seek alternative routes. Also, a behavioral evaluation is required if it has not been performed previously."
Prager's patients are still paying out of pocket in most cases, as third-party payers rarely cover it.
"The total global fee for infusion, including facility costs, medications and professional fees, ranges from $2000 to $2300," Prager said. As to whether more pain management physicians should begin offering ketamine infusion to patients with CRPS, Prager said, "Not unless they have a large experience with CRPS and an infrastructure to support it."
For one thing, Prager said, continuing with physical therapy is essential. He continues to prescribe it for patients, but that is something he has been doing even before the ketamine infusions began, and even if a patient is not undergoing ketamine infusion.
Those with CRPS (or their parents) are also learning about induced coma through ketamine that has been performed in Mexico and Germany. No trial in the United States has been done or planned, as far as Topics in Pain Management is able to learn.
"There are many constraints here," Prager said, adding that it would take a rigorous study conducted in the United States before it would ever be accepted by the medical and insurance establishment.
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